Mega Doctor News
- Advertisement -
By George Washington University
Newswise — A major shift is coming to the GLP-1 weight loss drug market in 2026 — one that could dramatically change who can access these medications, how they’re taken, and how much they cost.
After years defined by shortages, high prices, and weekly injections, GLP-1 drugs like Wegovy and Zepbound are entering a new era. Oral weight loss pills are arriving, competition is increasing, and cash-pay programs and retailer partnerships are reshaping access for people whose insurance doesn’t cover obesity treatment.
- Advertisement -
What’s changing:
- First GLP-1 weight loss pill approved: Novo Nordisk’s oral Wegovy is expected to be widely available, with another pill from Eli Lilly likely later this year — offering a needle-free option many patients prefer.
- Lower prices, more competition: Starting doses of GLP-1 pills are expected to cost as little as $149 a month for cash-paying patients, compared with $349 or more for injections.
- More powerful injections on the horizon: Lilly’s experimental drug retatrutide produced nearly 29% average weight loss in trials — the highest seen yet — but with higher dropout rates due to side effects.
- Advertisement -
